Little is known regarding the influence of these obesity-related inflammatory pathways on the efficacy of asthma biologics and whether measurement of serum IL-6, IL-17 or adiponectin levels may predict response to biologic therapies in patients with asthma. The gene discussed is IL17A; the disease is asthma.